Morgan Stanley
BIS icon

Morgan Stanley’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Morgan Stanley’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$21 – 8429
2026
Q1 		$21 Hold
1
– – ﹤0.01% 8160
2025
Q4 		$15 Buy
+1
New +$21 ﹤0.01% 8108
2025
Q3 		– Sell
-1
Closed -$47 – 8178
2025
Q2 		$47 Sell
1
-37
-97% -$1.41K ﹤0.01% 7801
2025
Q1 		$1.42K Hold
38
– – ﹤0.01% 7236
2024
Q4 		$1.37K Buy
38
+1
+3% +$32 ﹤0.01% 7241
2024
Q3 		$1.11K Sell
37
-1
-3% -$30 ﹤0.01% 7210
2024
Q2 		$1.25K Sell
38
-44
-54% -$1.6K ﹤0.01% 7129
2024
Q1 		$2.87K Sell
82
-80
-49% -$2.83K ﹤0.01% 7011
2023
Q4 		$5.85K Buy
162
+101
+166% +$4.6K ﹤0.01% 6970
2023
Q3 		$2.71K Hold
61
– – ﹤0.01% 7061
2023
Q2 		$2.52K Sell
61
-15
-20% -$595 ﹤0.01% 7141
2023
Q1 		$3.06K Buy
76
+22
+41% +$875 ﹤0.01% 7157
2022
Q4 		$2.1K Hold
54
– – ﹤0.01% 7363
2022
Q3 		$3K Buy
54
+16
+42% +$758 ﹤0.01% 7365
2022
Q2 		$2K Sell
38
-54
-59% -$3.02K ﹤0.01% 7568
2022
Q1 		$4K Sell
92
-99
-52% -$5.05K ﹤0.01% 7623
2021
Q4 		$8K Buy
191
+100
+110% +$3.92K ﹤0.01% 7523
2021
Q3 		$3K Buy
+91
New +$3.17K ﹤0.01% 7593
2021
Q2 		– Sell
-49
Closed -$2K – 7743
2021
Q1 		$2K Sell
49
-345
-88% -$14.5K ﹤0.01% 7251
2020
Q4 		$19K Buy
394
+203
+106% +$11.1K ﹤0.01% 6442
2020
Q3 		$12K Buy
191
+111
+139% +$7.09K ﹤0.01% 6209
2020
Q2 		$5K Sell
80
-880
-92% -$68.5K ﹤0.01% 6289
2020
Q1 		$108K Buy
960
+871
+979% +$99.5K ﹤0.01% 5153
2019
Q4 		$9K Buy
89
+20
+29% +$2.57K ﹤0.01% 6281
2019
Q3 		$11K Sell
69
-51
-43% -$7.49K ﹤0.01% 6168
2019
Q2 		$16K Buy
120
+72
+150% +$10.5K ﹤0.01% 6000
2019
Q1 		$6K Buy
48
+47
+4,700% +$6.64K ﹤0.01% 6286
2018
Q4 		$0 Buy
+1
New +$161 ﹤0.01% 6595
2018
Q1 		– Sell
-142
Closed -$25K – 6609
2017
Q4 		$25K Sell
142
-113
-44% -$20.1K ﹤0.01% 6019
2017
Q3 		$42K Sell
255
-610
-71% -$110K ﹤0.01% 5835
2017
Q2 		$168K Buy
865
+632
+271% +$138K ﹤0.01% 5422
2017
Q1 		$52K Sell
233
-466
-67% -$110K ﹤0.01% 5815
2016
Q4 		$196K Buy
699
+632
+943% +$173K ﹤0.01% 5363
2016
Q3 		$17K Buy
67
+21
+46% +$5.57K ﹤0.01% 5953
2016
Q2 		$15K Sell
46
-636
-93% -$201K ﹤0.01% 5939
2016
Q1 		$238K Sell
682
-760
-53% -$264K ﹤0.01% 4875
2015
Q4 		$331K Sell
1,442
-782
-35% -$201K ﹤0.01% 4809
2015
Q3 		$686K Sell
2,224
-1,209
-35% -$285K ﹤0.01% 4398
2015
Q2 		$789K Buy
3,433
+3,210
+1,439% +$796K ﹤0.01% 4376
2015
Q1 		$61K Sell
223
-71
-24% -$21.7K ﹤0.01% 5721
2014
Q4 		$108K Sell
294
-391
-57% -$163K ﹤0.01% 5516
2014
Q3 		$330K Buy
685
+664
+3,162% +$353K ﹤0.01% 4848
2014
Q2 		$12K Buy
+21
New +$14.5K ﹤0.01% 6147

Other funds holding BIS

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley's BIS Position: Q2 2026 in Review

Morgan Stanley sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q2 2026, closing a stake of 1 share — an estimated $21 sold.

Morgan Stanley first reported a position in BIS in Q2 2014 and held it in 43 quarters. The position peaked at $789K in Q2 2015. 2 funds tracked by Wall St. Rank hold BIS as of Q2 2026.

  • Morgan Stanley reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Morgan Stanley sold 1 ProShares UltraShort NASDAQ Biotechnology share in Q2 2026, an estimated $21.
  • Morgan Stanley first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2014 and held it in 43 quarters.
  • Morgan Stanley's ProShares UltraShort NASDAQ Biotechnology position peaked at $789K in Q2 2015.
  • 2 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.